Article
BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes.
Clinical epigenetics - 11 Nov 2020
Wasiak Sylwia, Dzobo Kim E, Rakai Brooke D, Kaiser Yannick, Versloot Miranda, Bahjat Mahnoush, Stotz Stephanie C, Fu Li, Sweeney Michael, Johansson Jan O, Wong Norman C W, Stroes Erik S G, Kroon Jeffrey, Kulikowski Ewelina
Abstract excerpt
BACKGROUND: Patients with cardiovascular disease (CVD) and type 2 diabetes (DM2) have a high residual risk for experiencing a major adverse cardiac event. Dysregulation of epigenetic mechanisms of gene transcription in innate immune cells contributes to CVD development but is currently not targeted by therapies. Apabetalone (RVX-208) is a small molecule inhibitor of bromodomain and extra-terminal (BET)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
